Streetbeat News

Price Targets

ACAD

Cantor Fitzgerald analyst Sarah James maintains an Overweight rating on ACADIA Pharmaceuticals and raises the price target from $36 to $42.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:52 pm

BHVN

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Biohaven (NYSE:BHVN) and maintained a price target of $31.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:51 pm

GDRX

Morgan Stanley analyst Ricky Goldwasser maintains an Equal-Weight rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $6 to $8.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:51 pm

ABOS

Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Acumen Pharmaceuticals (NASDAQ:ABOS) and maintained a $13 price target.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:51 pm

RMTI

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Rockwell Medical (NASDAQ:RMTI) and raises the price target from $9 to $11.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:51 pm

ARAV

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Aravive (NASDAQ:ARAV) and maintained a price target of $18.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:50 pm

GMAB

Morgan Stanley analyst Matthew Harrison has reiterated an 'Underweight' rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:49 pm

XENE

RBC Capital analyst Brian Abrahams has reiterated his 'Outperform' rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a price target of $51.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:48 pm

GLPG

Morgan Stanley analyst James Quigley has reiterated an Equal-Weight rating on Galapagos (NASDAQ:GLPG) and maintained a $42 price target.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:48 pm

UNH

RBC Capital analyst Ben Hendrix has maintained an 'Outperform' rating on UnitedHealth Group (NYSE:UNH) but lowered the price target from $592 to $572.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:47 pm